TLDR:
– Taiho Ventures, a strategic corporate venture capital arm of Taiho Pharmaceutical, has increased its investment pool from $300 million to $400 million.
– The firm seeks to invest in promising start-up companies conducting innovative drug discovery and platform technologies in the oncology field.
Taiho Ventures, the strategic corporate venture capital arm of Taiho Pharmaceutical, has expanded its investment pool from $300 million to $400 million. The firm aims to continue its support for innovative biotech start-ups focusing on cutting-edge drug discovery in the oncology field. Taiho Ventures has already built an investment portfolio comprising more than 25 companies, including Arcus Biosciences, Cullinan Pearl, and Werewolf Therapeutics. The expansion of its investment pool demonstrates Taiho Ventures’ commitment to supporting start-ups dedicated to advancing scientific discovery and improving patient well-being.
Taiho Ventures was established in 2016 with a focus on exploring investment opportunities in early-stage start-ups that are engaged in oncology research and platform technologies. The firm seeks to support companies conducting innovative drug discovery and development activities. By expanding its investment pool, Taiho Ventures aims to enhance its ability to invest in promising start-ups around the world.
The increased investment pool demonstrates Taiho Ventures’ commitment to supporting innovative biotech start-ups. Taiho Pharmaceutical, the parent company, also aims to accelerate open innovation through these investment efforts. The overall goal is to deliver new technologies and treatment options to patients in need, improving their quality of life and providing hope for better health outcomes in the future.
Taiho Pharmaceutical is a subsidiary of Otsuka Holdings and specializes in oncology and allergy/immunology. It is known for developing innovative medicines for the treatment of cancer and focuses on delivering quality products that improve people’s well-being in various medical fields. Taiho Ventures serves as the strategic corporate venture capital arm of Taiho Pharmaceutical and seeks to invest in early-stage preclinical oncology companies and platform technology companies in related therapeutic areas. The company aims to review a wide variety of modalities, including biologics and small molecules, and explore options for equity investments, spin-outs, and other types of strategic investments. By expanding its investment pool, Taiho Ventures can continue to support innovative biotech start-ups and contribute to the advancement of breakthrough drug discovery and development.
